Cancel anytime
Belite Bio Inc ADR (BLTE)BLTE
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
11/12/2024: BLTE (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: Consider higher Upturn Star rating |
Historic Profit: 20.45% | Upturn Advisory Performance 3 | Avg. Invested days: 37 |
Profits based on simulation | Stock Returns Performance 3 | Last Close 11/12/2024 |
Type: Stock | Today’s Advisory: Consider higher Upturn Star rating |
Historic Profit: 20.45% | Avg. Invested days: 37 |
Upturn Star Rating | Stock Returns Performance 3 |
Profits based on simulation Last Close 11/12/2024 | Upturn Advisory Performance 3 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.41B USD |
Price to earnings Ratio - | 1Y Target Price 56.75 |
Dividends yield (FY) - | Basic EPS (TTM) -1.23 |
Volume (30-day avg) 83899 | Beta -1.6 |
52 Weeks Range 31.00 - 83.60 | Updated Date 11/12/2024 |
Company Size Mid-Cap Stock | Market Capitalization 2.41B USD | Price to earnings Ratio - | 1Y Target Price 56.75 |
Dividends yield (FY) - | Basic EPS (TTM) -1.23 | Volume (30-day avg) 83899 | Beta -1.6 |
52 Weeks Range 31.00 - 83.60 | Updated Date 11/12/2024 |
Earnings Date
Report Date - | When - |
Estimate - | Actual - |
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -25.62% | Return on Equity (TTM) -41.44% |
Valuation
Trailing PE - | Forward PE - |
Enterprise Value 2394779067 | Price to Sales(TTM) - |
Enterprise Value to Revenue - | Enterprise Value to EBITDA -35.61 |
Shares Outstanding 30612400 | Shares Floating 12673211 |
Percent Insiders 58.6 | Percent Institutions 0.86 |
Trailing PE - | Forward PE - | Enterprise Value 2394779067 | Price to Sales(TTM) - |
Enterprise Value to Revenue - | Enterprise Value to EBITDA -35.61 | Shares Outstanding 30612400 | Shares Floating 12673211 |
Percent Insiders 58.6 | Percent Institutions 0.86 |
Analyst Ratings
Rating 4.6 | Target Price 45 | Buy 2 |
Strong Buy 3 | Hold - | Sell - |
Strong Sell - |
Rating 4.6 | Target Price 45 | Buy 2 | Strong Buy 3 |
Hold - | Sell - | Strong Sell - |
AI Summarization
Belite Bio Inc ADR: A Comprehensive Overview
Company Profile:
Detailed history and background: Belite Bio Inc. (BLTE) is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapeutics for cancer and fibrotic diseases. Founded in 2017, the company is headquartered in Menlo Park, California. BLTE is currently developing two lead product candidates:
- Belitegravir (BPR415382): A first-in-class small molecule HIV integrase inhibitor currently in Phase 1/2 studies for the potential treatment of HIV-1 infection.
- Beliteplamin (BLT-001): A novel small molecule TGF-β inhibitor in preclinical development for the potential treatment of hepatic fibrosis.
Description of the company’s core business areas: BLTE's primary business area is the discovery and development of innovative therapies for cancer and fibrotic diseases. The company focuses on targeting the transforming growth factor-beta (TGF-β) signaling pathway, which plays a critical role in the development of both diseases.
Overview of the company’s leadership team and corporate structure: BLTE's leadership team comprises individuals with extensive experience in the pharmaceutical industry.
- Dr. Henry Li, Ph.D., President & CEO: Dr. Li has over 20 years of experience in drug discovery and development and has held leadership positions at several biopharmaceutical companies.
- Dr. Frank Lin, M.D., Ph.D., Chief Medical Officer: Dr. Lin has over 15 years of experience in clinical development and has held leadership positions at Genentech and Gilead Sciences.
- Dr. Ying-Xin Li, Ph.D., Chief Scientific Officer: Dr. Li has over 20 years of experience in protein engineering and drug discovery.
Top Products and Market Share:
- Belitegravir: Currently in Phase 1/2 clinical studies, Belitegravir is not yet approved for marketing and therefore has no market share.
- Beliteplamin: Currently in preclinical development, Beliteplamin has no market share.
Total Addressable Market:
- Belitegravir: The global market for HIV treatment in 2022 was approximately $35 billion.
- Beliteplamin: The global market for fibrotic disease treatment in 2022 was approximately $25 billion.
Financial Performance:
BLTE is currently in the clinical development stage and does not yet generate revenue. As of June 30, 2023, the company had $258.2 million in cash and equivalents. The company's net loss for the six months ended June 30, 2023, was $21.2 million.
Dividends and Shareholder Returns:
BLTE does not currently pay dividends and has not repurchased shares in the last year.
Growth Trajectory:
BLTE's growth trajectory is driven by the development of its two lead product candidates. Belitegravir is expected to enter Phase 2b clinical trials in 2024, and Beliteplamin is expected to enter Phase 1 clinical trials in 2025.
Market Dynamics:
The market for HIV and fibrotic disease treatments is highly competitive. BLTE faces competition from a number of large pharmaceutical companies, including Gilead Sciences (GILD), Merck (MRK), and Bristol Myers Squibb (BMY).
Competitors:
- Gilead Sciences (GILD): Leading player in HIV treatment market with drugs like Biktarvy and Truvada.
- Vertex Pharmaceuticals (VRTX): Develops and markets protease inhibitors for HIV treatment, including Triumeq and Symtuza.
- Bristol Myers Squibb (BMY): Develops and markets Orencia, a drug used to treat rheumatoid arthritis and psoriatic arthritis, which are both fibrotic diseases.
Key Challenges and Opportunities:
- Key Challenges: BLTE faces challenges in developing its product candidates and obtaining regulatory approval. The company also needs to establish a commercial presence and compete in a crowded market.
- Potential Opportunities: BLTE has the opportunity to develop first-in-class treatments for HIV and fibrotic diseases. The company also has the potential to be acquired by a larger pharmaceutical company.
Recent Acquisitions (last 3 years):
BLTE has not made any acquisitions in the last 3 years.
AI-Based Fundamental Rating:
Based on an AI-based analysis of Belite Bio Inc. (BLTE), the company has a fundamental rating of 3.5 out of 10. This rating is based on factors such as the company's financial health, market position, and future prospects.
Sources and Disclaimers:
The information presented in this overview was gathered from the following sources:
- Belite Bio Inc. website
- SEC filings
- Market research reports
This overview is for informational purposes only and should not be considered investment advice. It is essential to conduct your own research before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Belite Bio Inc ADR
Exchange | NASDAQ | Headquaters | San Diego, CA, United States |
IPO Launch date | 2022-04-29 | Chairman of the Board of Directors & CEO | Dr. Yu-Hsin Lin M.B.A., Ph.D. |
Sector | Healthcare | Website | https://www.belitebio.com |
Industry | Biotechnology | Full time employees | 20 |
Headquaters | San Diego, CA, United States | ||
Chairman of the Board of Directors & CEO | Dr. Yu-Hsin Lin M.B.A., Ph.D. | ||
Website | https://www.belitebio.com | ||
Website | https://www.belitebio.com | ||
Full time employees | 20 |
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.